NCT03884517: Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: Trop2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be positive for Trop2 expression
Exclusions: Patients with symptoms of brain or other central nervous system metastasis

Comments are closed.

Up ↑